Alpha Teknova, Inc.
NASDAQ•TKNO
CEO: Mr. Stephen Gunstream
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2021-06-25
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Contact Information
Market Cap
$118.30M
P/E (TTM)
-6.9
37.5
Dividend Yield
--
52W High
$7.48
52W Low
$1.91
52W Range
Rank48Top 64.4%
3.3
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Financial Dashboard
Q4 2025 Data
Revenue
$9.98M+0.00%
4-Quarter Trend
EPS
-$0.09+0.00%
4-Quarter Trend
FCF
-$710.00K+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Growth Achieved Revenue reached $40.520M, increasing 7.4% from $37.745M in 2024, driven by Lab Essentials segment growth.
Gross Margin Expansion Gross profit increased 85.9% to $13.441M; margin improved significantly to 33.2% from 19.2% reported.
Net Loss Reduction Net loss reduced by $9.486M to $(17.259)M, reflecting a 35.5% improvement in overall operating results.
Positive Investing Cash Flow Net cash provided by investing activities was $10.700M, resulting from $29.000M in short-term investment maturities.
Risk Factors
Historical Losses Persist Past operating losses incurred; future profitability uncertain if revenue growth fails to offset increasing operating expenses.
Supply Chain Disruption Risk Supply chain disruption from natural disasters or catastrophic events could negatively affect production, delivery, and product demand.
Customer Relationship Reliance Reliance on customer relationships; termination of major orders could cause temporary or permanent revenue loss.
Uncertain Future Capital Needs Future capital needs are uncertain; financing may be required but securing favorable terms is not assured.
Outlook
Deepen Customer Workflow Integration Strategy focuses on increasing integration of custom and GMP products into customer development workflows for sustained growth.
Selective Geographic Expansion Plan to expand geographic reach outside the U.S., targeting select European markets with local supply gaps.
Growth in Therapeutic Modalities Expect growth driven by continued R&D investment in cell/gene therapy, mRNA, and molecular diagnostics markets.
Infrastructure Investment Commit to operational excellence via infrastructure investment to increase capacity and reduce custom product turnaround times.
Peer Comparison
Revenue (TTM)
$727.33M
$296.15M
$278.39M
Gross Margin (Latest Quarter)
100.0%
100.0%
99.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| IRWD | $588.90M | 24.5 | -10.0% | 53.6% |
| CGC | $535.10M | -1.5 | -52.9% | 23.1% |
| IMMP | $406.25M | -6.8 | -69.2% | 0.8% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.6%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data